• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Schall Thomas J.

    6/16/25 9:15:35 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMRX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Schall Thomas J.

    (Last) (First) (Middle)
    C/O IMMUNEERING CORPORATION
    245 MAIN STREET, 2ND FLOOR

    (Street)
    CAMBRIDGE MA 02142

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Immuneering Corp [ IMRX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/13/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option $1.9 06/13/2025 A 33,350 (1) 06/13/2035 Class A Common Stock 33,350 $0 33,350 D
    Explanation of Responses:
    1. The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 13, 2025, and will be fully vested and exercisable on June 13, 2026, or the date of the 2026 annual meeting of stockholders, whichever comes first.
    Remarks:
    /s/ Michael D. Bookman, Attorney-in-Fact for Thomas J. Schall 06/16/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $IMRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMRX

    DatePrice TargetRatingAnalyst
    12/13/2024Equal-Weight → Underweight
    Morgan Stanley
    3/15/2024$20.00 → $15.00Buy
    Needham
    3/15/2024Outperform → Market Perform
    TD Cowen
    3/15/2024$16.00 → $3.00Buy → Hold
    Jefferies
    12/1/2023$20.00Buy
    Needham
    6/26/2023$25.00Outperform
    Oppenheimer
    4/19/2023$5.00 → $14.00Underweight → Equal-Weight
    Morgan Stanley
    4/19/2023$10.00 → $20.00Neutral → Buy
    Mizuho
    More analyst ratings

    $IMRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRESIDENT AND CEO Zeskind Benjamin J. bought $50,144 worth of shares (21,000 units at $2.39), increasing direct ownership by 0.92% to 2,302,852 units (SEC Form 4)

      4 - Immuneering Corp (0001790340) (Issuer)

      6/20/25 9:09:33 AM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Schall Thomas J. bought $89,278 worth of shares (40,485 units at $2.21), increasing direct ownership by 1,396% to 43,385 units (SEC Form 4)

      4 - Immuneering Corp (0001790340) (Issuer)

      6/18/25 9:11:22 AM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schall Thomas J. bought $7,385 worth of shares (2,900 units at $2.55) (SEC Form 4)

      4 - Immuneering Corp (0001790340) (Issuer)

      3/25/24 4:03:33 PM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Immuneering Corporation downgraded by Morgan Stanley

      Morgan Stanley downgraded Immuneering Corporation from Equal-Weight to Underweight

      12/13/24 8:04:38 AM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham reiterated coverage on Immuneering Corporation with a new price target

      Needham reiterated coverage of Immuneering Corporation with a rating of Buy and set a new price target of $15.00 from $20.00 previously

      3/15/24 7:50:35 AM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immuneering Corporation downgraded by TD Cowen

      TD Cowen downgraded Immuneering Corporation from Outperform to Market Perform

      3/15/24 7:19:50 AM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

      - Reported Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors - - First Patient Dosed in Phase 2a Portion of Phase 1/2a Clinical Trial of IMM-1-104; Initial Data from Multiple IMM-1-104 Phase 2a Arms Expected in 2024 - - Presented Preclinical Data at AACR Demonstrating that Combining IMM-1-104 with Chemotherapies Used in The Treatment of First-line Pancreatic Cancer Yielded Deeper and More Durable Tumor Growth Inhibition Than Either Treatment Alone - - First Patient Dosed in Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations; Initial PK, PD and safety data expected in 2024 - CAMBRIDGE

      5/7/24 4:05:00 PM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors

      CAMBRIDGE, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced the appointment of Thomas J. Schall, Ph.D., former Chairman, CEO and Founder of ChemoCentryx before its acquisition by Amgen, to its Board of Directors. "On behalf of the entire Immuneering team, we are honored to welcome Dr. Schall to our Board," said Ben Zeskind, Chief Executive Officer, Immuneering Corporation. "Tom's extensive experience developing new medicines, including 25 years guiding drug discovery, development and commercialization

      3/12/24 8:00:00 AM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates

      - Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program presented at American Association for Cancer Research (AACR) annual meeting - -First demonstration of novel deep cyclic inhibition mechanism in humans, with IMM-1-104 achieving significant levels of PK Cmax and a half-life of approximately two hours as predicted - - Study timeline for IMM-1-104 accelerated: recommended Phase 2 dose (RP2D) now expected in early 2024- - Pharmacodynamic data support potential to evaluate preliminary efficacy sooner than expected - - Completed $30 million underwritten offering; Projected cash runway extended into 2025 - CAMBRIDGE, Mass., May

      5/4/23 4:05:00 PM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology

      USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 20, 2025 /PRNewswire/ -- USA News Group News Commentary – The costs of cancer drugs is skyrocketing, according to a recent report from Bloomberg. Analysts at Nova One Advisor estimate that the global oncology drugs market will grow at a 7.4% CAGR through to US$366.24 billion by 2034. Help doesn't appear to be coming from the public sector, as reports state that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment.

      6/20/25 9:21:00 AM ET
      $GRAL
      $IMRX
      $INTS
      $ONCY
      Medical Specialities
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients

      - 94% OS and 72% PFS observed at 6 months for atebimetinib (IMM-1-104) in combination with modified Gemcitabine/nab-paclitaxel (mGnP), N=34; median OS and PFS not yet reached - - Striking tumor reductions with 39% overall response rate and 81% disease control rate observed as of the data cutoff, including many patients with deepening, durable regressions and multiple examples of individual lesions rendered undetectable - - Markedly favorable tolerability profile observed, demonstrating potential best-in-class profile - - Pivotal trial of atebimetinib in combination with mGnP in first-line pancreatic cancer patients planned for 2026 - - Company to host conference call at 8:00 a.m

      6/17/25 6:00:00 AM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025

      CAMBRIDGE, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company outpacing cancer to help patients outlive their disease, today announced that it will host a conference call and live webcast at 8:00 am ET on June 17, 2025. The company is excited to provide updates from its ongoing Phase 2a clinical trial of IMM-1-104 in first-line pancreatic cancer patients. The conference call will be webcast live and archived in the Investor Relations section of Immuneering's website at Events & Presentations | Immuneering Corporation. About Immuneering Corporation Immuneering is a clinical-stage oncology company outpacing cancer to help pati

      6/16/25 8:00:00 AM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRESIDENT AND CEO Zeskind Benjamin J. bought $50,144 worth of shares (21,000 units at $2.39), increasing direct ownership by 0.92% to 2,302,852 units (SEC Form 4)

      4 - Immuneering Corp (0001790340) (Issuer)

      6/20/25 9:09:33 AM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Schall Thomas J. bought $89,278 worth of shares (40,485 units at $2.21), increasing direct ownership by 1,396% to 43,385 units (SEC Form 4)

      4 - Immuneering Corp (0001790340) (Issuer)

      6/18/25 9:11:22 AM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Hausman Diana

      4 - Immuneering Corp (0001790340) (Issuer)

      6/16/25 9:21:28 AM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMRX
    SEC Filings

    See more
    • Immuneering Corporation filed SEC Form 8-K: Other Events

      8-K - Immuneering Corp (0001790340) (Filer)

      6/17/25 6:09:26 AM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immuneering Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Immuneering Corp (0001790340) (Filer)

      6/16/25 8:44:04 AM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Immuneering Corporation

      10-Q - Immuneering Corp (0001790340) (Filer)

      5/5/25 4:34:07 PM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Immuneering Corporation

      SC 13G/A - Immuneering Corp (0001790340) (Subject)

      11/14/24 4:15:35 PM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Immuneering Corporation

      SC 13G/A - Immuneering Corp (0001790340) (Subject)

      11/14/24 3:03:47 PM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Immuneering Corporation (Amendment)

      SC 13G/A - Immuneering Corp (0001790340) (Subject)

      4/15/24 6:10:57 PM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMRX
    Financials

    Live finance-specific insights

    See more
    • Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients

      - 94% OS and 72% PFS observed at 6 months for atebimetinib (IMM-1-104) in combination with modified Gemcitabine/nab-paclitaxel (mGnP), N=34; median OS and PFS not yet reached - - Striking tumor reductions with 39% overall response rate and 81% disease control rate observed as of the data cutoff, including many patients with deepening, durable regressions and multiple examples of individual lesions rendered undetectable - - Markedly favorable tolerability profile observed, demonstrating potential best-in-class profile - - Pivotal trial of atebimetinib in combination with mGnP in first-line pancreatic cancer patients planned for 2026 - - Company to host conference call at 8:00 a.m

      6/17/25 6:00:00 AM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025

      CAMBRIDGE, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company outpacing cancer to help patients outlive their disease, today announced that it will host a conference call and live webcast at 8:00 am ET on June 17, 2025. The company is excited to provide updates from its ongoing Phase 2a clinical trial of IMM-1-104 in first-line pancreatic cancer patients. The conference call will be webcast live and archived in the Investor Relations section of Immuneering's website at Events & Presentations | Immuneering Corporation. About Immuneering Corporation Immuneering is a clinical-stage oncology company outpacing cancer to help pati

      6/16/25 8:00:00 AM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms

      - Updated data for IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients show favorable overall response rate (ORR = 43%) and disease control rate (DCR = 86%); planning for pivotal trial underway - - Favorable initial data for IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer patients show target lesion shrinkage in all evaluable patients, including a 100% reduction (PR) - - Encouraging initial data for IMM-1-104 monotherapy in second-line pancreatic cancer, including a 67% reduction (PR), demonstrate activity and support development in first-line combinations; over 75 patients enrolled acros

      1/7/25 7:00:00 AM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care